Related Experiment Videos
Coxibs: a significant therapeutic opportunity
1Rheumatology Unit, Department of Medicine, University of Verona, Italy. davide.gatti@univr.it
Acta Bio-Medica : Atenei Parmensis
|April 26, 2012
Summary
Coxibs (COX-2 selective inhibitors) offer better gastrointestinal safety than traditional NSAIDs for osteoarticular pain. Cardiovascular risk is similar to NSAIDs, making coxibs a valid therapeutic option.
Area of Science:
- Pharmacology
- Gastroenterology
- Cardiology
Background:
- Osteoarticular conditions like arthrosis are common causes of pain, often treated with anti-inflammatory drugs.
- Paracetamol is a first-line treatment but often insufficient, while conventional NSAIDs have unfavorable safety profiles, especially gastric issues.
- Coxibs (COX-2 selective inhibitors) were developed to reduce NSAID-related gastrointestinal complications.
Purpose of the Study:
- To evaluate the efficacy and safety of coxibs compared to conventional NSAIDs in managing pain associated with osteoarticular conditions.
- To assess the gastrointestinal and cardiovascular risks associated with coxib use.
Main Methods:
- Review of clinical studies and trials comparing coxibs with conventional NSAIDs and placebo.
- Analysis of data on gastroduodenal ulcer rates, treatment discontinuation due to gastrointestinal symptoms, and cardiovascular events.
- Examination of pathogenetic hypotheses for cardiovascular risk and findings from trials like MEDAL.
Main Results:
- Coxibs demonstrate significantly lower rates of gastroduodenal ulcers and related complications compared to conventional NSAIDs.
- The gastrointestinal safety profile of coxibs is comparable to the combination of NSAIDs with proton-pump inhibitors.
- Cardiovascular risk associated with coxibs, such as etoricoxib, is similar to that of conventional NSAIDs like diclofenac, as confirmed by the MEDAL trial.
Conclusions:
- Coxibs are a valid therapeutic option for osteoarticular conditions, offering superior gastrointestinal safety.
- The cardiovascular risk profile of coxibs is comparable to conventional NSAIDs.
- Etoricoxib shows equivalent anti-inflammatory and pain-relieving efficacy to other NSAIDs.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...